Skip to content
DataLookout
Menu

NCT07018388

Intrapatient Comparison of STN and GPi tTIS in PD

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Apr 23, 2025 to Aug 25, 2025 Show 6 more changesShow less
    • Eligibility criteria expanded, about 7 words
    • Trial status changed: Enrolling by Invitation → Completed
    • Final enrollment: 30 participants (planned 100)
    • Primary completion date changed from estimate of Nov 1, 2026 to Apr 10, 2026
    • Interventions modified
    • Secondary endpoints: 1 to 2
  2. Notable Primary and study completion dates pushed to Nov 1, 2026
    • Enrollment increased: 30 → 100 participants
    v3
  3. Notable Enrollment target: 20 to 30v2 Show 6 more changesShow less
    • Primary completion date: Jun 20, 2025 to Feb 28, 2026
    • Eligibility criteria shortened, about 2 words
    • Study completion date: Jun 30, 2025 to Mar 15, 2026
    • Interventions: NervioX-2400 (Device), NervioX-2400 (Device) to NervioX-2400 (Device), NervioX-2400 (Device), NervioX-2400 (Device)
    • Study description expanded, about 12 words
    • Study arms: 2 to 3
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

MDS-UPDRS-Ⅲ scores
Timeframe: pre-intervention, immediately after the intervention

Secondary (2)

MDS-UPDRS-Ⅲ sub-scores
Number of participants with adverse events

Arms and interventions

STN-tTISExperimental

Patients in this group receive 20 minutes of individualized 130 Hz STN-tTIS sessions targeting the more affected hemisphere during medication "off" and are evaluated for the MDS-UPDRS-Ⅲ before and after treatment.

GPi-tTISExperimental

Patients in this group receive 20 minutes of individualized 130 Hz GPi-tTIS sessions targeting the more affected hemisphere during medication "off" and are evaluated for the MDS-UPDRS-Ⅲ both before and after treatment.

Sham stimulationExperimental

Patients in this group receive sham stimulation targeting the subthalamic nucleus in the more affected hemisphere during the medication "off" state. Sham uses each participant's own STN-tTIS montage, with both channels delivering 2000 Hz so that the stimulation beat frequency is 0 Hz and no interference envelope is produced. Current is ramped up over 30 seconds and back to 0 mA over the next 30 seconds, with no stimulation for the remainder of the session. Each session lasts 20 minutes, and the MDS-UPDRS-III is assessed both before and after treatment.

Devices: Transcranial temporal interference stimulation

Sites

1 site in 1 country

  • Ruijin HospitalShanghai, Shanghai Municipality, China